"Designing Growth Strategies is in our DNA"

Monoclonal Antibody Therapy Market Size, Share & COVID-19 Impact Analysis, By Type (Human mAb, Humanized mAb, Chimeric mAb, and Murine mAb), By Application (Cancer, Autoimmune Diseases, and Others), By Distribution Channel (Hospital Pharmacy Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2021-2028

Region : Global | Format: PDF | Report ID: FBI102734

 

KEY MARKET INSIGHTS

Play Audio Listen to Audio Version

The global monoclonal antibody therapy market size was USD 157.33 billion in 2020. The global impact of COVID-19 has been unprecedented and staggering, with mAb therapeutics witnessing a negative demand shock across all regions amid the pandemic. Based on our analysis, the global market exhibited a decline of -5.6% in 2020 as compared to the average year-on-year growth during 2017-2019. The market is projected to grow from USD 178.50 billion in 2021 to USD 451.89 billion in 2028 at a CAGR of 14.1% in the 2021-2028 period. The sudden rise in CAGR is attributable to this market’s demand and growth, returning to pre-pandemic levels once the pandemic is over.


In the current scenario, monoclonal antibody therapy is growing at an unprecedented success, revenue growth, accelerated research, and traction owing to their effective clinical outcomes. Monoclonal antibodies such as Remicade, Rituxan, Remicade, Humira, and Herceptin have emerged as blockbuster drugs, which are in turn boosting the market. Apart from this, the market is being flooded by numerous biosimilars owing to less cost, easy approval process, and patent expiry. This is also driving the growth of the market.


Increasing research and development funding for the development of novel monoclonal antibodies is expected to favor the market during the forecast period. In December 2019, CARsgen Therapeutics received Investigational New Drug (IND) clearance in China for AB011, a humanized monoclonal antibody for the treatment of gastric and pancreatic adenocarcinoma. This is expected to positively impact the global market.


Supply Chain Disruption and Lower Product Demand Impacted Sales amid COVID-19 Pandemic


Due to the unprecedented occurrence of the coronavirus pandemic, the healthcare industry underwent a major setback at the initial stage of the supply chain. The key players in the monoclonal antibodies therapeutics market experienced a decline in the sales growth for their products. Amid the pandemic, the top-selling drug in the market, Humira, witnessed a positive growth of 4% as compared to the year 2019. However, some drugs such as Roche’s Herceptin, Avastin as well as J&J’s Remicade observed a decline in the revenues owing to the lower demand as compared to the year 2019.


In a different scenario, the COVID-19 pandemic has boosted the R&D sector of the companies with an aim to launch mAbs-based COVID-19 treatment in the market. For instance, in November 2020, U.S FDA granted emergency use authorization (EUA) to Regeneron Pharmaceuticals monoclonal antibodies casirivimab and imdevimab for treatment of COVID-19. Therefore, such innovations are anticipated to impact the sales of the global market during the forecast period.


LATEST TRENDS


Request a Free sample to learn more about this report.


Strategic Research Collaborations Will Open New Growth Opportunities


The increased focus of pharmaceutical giants on the development of novel monoclonal antibodies has paved the way for major research collaborations, which are emerging as a key monoclonal antibody therapy market trends. Owing to the increasing adoption of these novel drugs, new manufacturers want to enter the highly competitive market, and strategic collaborations can be a useful tool to sustain their position. For example, in October 2017, Incyte and MacroGenics, Inc. announced a partnership and license agreement for MGA012, an investigational monoclonal antibody of MacroGenics, Inc.


DRIVING FACTORS


Significant Investment in Development of Novel Therapeutics to Boost Growth


Monoclonal antibody therapy is a fast emerging extraordinary tool as a treatment option for chronic diseases, especially cancer. Preference towards these drugs is gradually rising, resulting in blockbuster sales of few products such as Herceptin and Humira, among others. This, in turn, has encouraged major pharmaceutical companies for huge research investments in the field of monoclonal antibodies. For example, AstraZeneca, a pharmaceutical giant, is conducting a phase II clinical trial on Tezepelumab for the treatment of atopic dermatitis. Similarly, pipeline potential candidates are expected to drive the global market growth.


Apart from this, green signals from the regulatory authorities for the entry of biosimilars of existing products are further fostering the global market value.


Rising Prevalence of Chronic Diseases to Favor Market Growth


The increasing prevalence of chronic diseases such as cancer is one of the major factors augmenting the growth of the global market. Chronic diseases pose a major burden across the globe which is propelling the governments of various countries to put efforts in reducing the cost burden pertaining to their spread. According to the Centers for Disease Control and Prevention, 6 in every ten adults in the U.S. are suffering from a chronic disease, leading to an annual healthcare cost of US$ 3.5 trillion. Furthermore, unmet patient needs and improving health reimbursement policies for therapeutic monoclonal antibodies used as a treatment option for chronic diseases are projected to fuel the monoclonal antibody therapy market growth.


RESTRAINING FACTORS


Stringent Regulatory Policies for Approval Process to Hamper Market Growth


Despite promising results for monoclonal antibodies in the treatment of various diseases, the long and strict regulations for approval and launch will be a major hindrance to the monoclonal antibodies therapy revenue. Many clinical studies are withdrawn mainly due to failure to meet the stringent regulations and end results framed by the regulatory authorities. In addition to this, potential side effects of these drugs are other factors restricting the monoclonal antibody therapy market growth.


SEGMENTATION


By Type Analysis


To know how our report can help streamline your business, Speak to Analyst


Human Monoclonal Antibody Segment to Dominate Market Owing to High Humira Sales


On the basis of type, the global market can be segmented into human mAb, humanized mAb, chimeric mAb, and murine mAb. The human mAb segment accounted for the dominating position. This can be attributed to the higher sales and demand for Humira. Moreover, the entry of Adalimumab biosimilars is expected to augment the segment during 2020-2027. For example, in October 2018, Amgen announced the launch of Amgevita, a biosimilar of adalimumab in Europe.


The humanized monoclonal antibody segment is poised to surge owing to the increased number of humanized mAb therapies and rising research funding by pharmaceutical companies. Genentech, a company of Roche, is conducting research on Obinutuzumab, a humanized anti-CD20 monoclonal antibody for the treatment of end-stage renal disease. This is likely to render remarkable growth to the humanized mAb segment. Technological advancement to develop a molecular-level understanding of diseases, rising aging population, and expanding applications of monoclonal antibodies are factors contributing to the expansion of the chimeric monoclonal antibody and murine monoclonal antibody segments.


By Application Analysis


Cancer Segment to Hold Largest Share Backed by Surging Number of Potential Pipeline Candidates  


Based on application, the global market is segmented into type cancer, autoimmune diseases, and others. The cancer segment accounted for the maximum portion of the market and is estimated to dominate the market throughout the forecast period. The rising prevalence of cancer, improving health reimbursement policies, and potential pipeline candidates are the major factors that contributed to the growth of the segment. According to the WHO, the number of cancer cases in the world is estimated to increase from 18.0 million in 2018 to 24.1 million by 2030. This is expected to augment the cancer segment.


The autoimmune disease segment is expected to grow owing to the rising incidences of rheumatoid arthritis, rapid adoption of biological therapies, and new product launches. The other segment is projected to expand during the forecast period owing to the emerging use of monoclonal antibody therapy for migraines, eczema, respiratory diseases, and others. 


By Distribution Channel Analysis


Hospital Pharmacy Segment to Account for Major Portion of This Market


In terms of distribution channels, the global market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment generated the maximum revenue in 2019 owing to the improving guidelines, favoring health reimbursement policies, and active government interventions for chronic diseases. The retail pharmacy segment is anticipated to grow during the forecast period mainly due to the increasing focus by manufacturers to expand distribution networks, a significant increase in the number of cancer cases, and improving health infrastructure. Growth of the online stores segment is likely to propel owing to the improving patient convenience, rising adoption of online channels, and attractive discounts and coupons on online sales.


REGIONAL INSIGHTS


North America Monoclonal Antibody Therapy Market Size, 2020 (USD Billion)

To get more information on the regional analysis of this market, Request a Free sample


The market size in North America stood at USD 75.19 billion in 2020. Factors attributed to the dominant share of North America are new product launches, increasing research funding and collaborations, and the increasing prevalence of chronic diseases. According to the National Cancer Institute, in 2020, there were 1.8 million new cancer cases in the U.S. This is estimated to increase the demand for monoclonal antibody based therapeutics in North America. In Europe, the market is poised to surge owing to favorable health reimbursement and easy approval and launch of biosimilars.


In October 2018, Biogen announced the launch of Imraldi, an adalimumab biosimilar, which will help the market to flourish in Europe. Rising incidences of arthritis and inflammatory diseases, increasing geriatric population, and growing preference for biosimilars are primary reasons for the expansion of the market in Asia Pacific. The market in the Middle East & Africa and Latin America is expected to gain significant momentum owing to the increased focus of manufacturers towards emerging countries, unmet patient needs, and improving health spending.


KEY INDUSTRY PLAYERS


AbbVie and F. Hoffmann-La Roche Ltd. to Hold Leading Position in This Market


In the global market, F. Hoffmann-La Roche Ltd., accounted for the maximum share, which can be attributed to the increasing sale of Herceptin. AbbVie, on the other hand, is ranked second in the market owing to the increased sales of Humira. In 2018, the company generated a sale of US$ 19.0 billion in 2019. Though Humira still has exclusivity in the U.S., the launch of adalimumab biosimilars in Europe is expected to affect the position of AbbVie.


LIST OF KEY COMPANIES PROFILED:



  • AbbVie Inc. (Illinois, United States)

  • Merck & Co., Inc. (New Jersey, United States)

  • F.Hoffmann-La Roche Ltd. (Basel, Switzerland)

  • Bristol-Myers Squibb Company (New York, United States)

  • Johnson & Johnson Services, Inc. (New Jersey, United States)

  • Daiichi Sankyo Company, Limited (Tokyo, Japan)

  • Novartis AG (Basel, Switzerland)

  • Alexion Pharmaceuticals, Inc.  (Massachusetts, United States)

  • Amgen Inc. (California, United States)

  • Others


KEY INDUSTRY DEVELOPMENTS:



  • December 2019 - CARsgen Therapeutics received Investigational New Drug (IND) clearance in China for AB011, a humanized mAb, for the treatment of gastric and pancreatic adenocarcinoma

  • October 2018 - Amgen announced the launch of Amgevita, a biosimilar of adalimumab in Europe.

  • October 2018 - In October 2018, Biogen announced the launch of Imraldi, an adalimumab biosimilar,

  • October 2017 - Incyte and MacroGenics, Inc. announced a partnership and license agreement for MGA012, an investigational mAb of MacroGenics, Inc.             


REPORT COVERAGE


An Infographic Representation of Monoclonal Antibody Therapy Market

To get information on various segments, share your queries with us



The global monoclonal antibody therapy market research report offers a detailed analysis of numerous factors affecting the market. These include opportunities, growth drivers, threats, key developments, competitive landscape, and restraints. In addition to this, the report further helps in analyzing, segmenting, and defining the market based on different segments such as type, application, and distribution channel. It strategically analyzes several strategies and provides various key insights such as the prevalence of major diseases for key countries, patent snapshot, pipeline analysis, new product launches, key mergers & acquisitions, joint ventures, and others.


Report Scope & Segmentation


















































  ATTRIBUTE



  DETAILS



Study Period



2017-2028



Base Year



2020



Forecast Period



2021-2028



Historical Period



2017-2019



Unit



Value (USD Billion)



Segmentation



Type; Application; Distribution Channel; and Geography



By Type




  • Human mAb

  • Humanized mAb

  • Chimeric mAb

  • Murine mAb



By Application




  • Cancer

  • Autoimmune Diseases

  • Others



By Distribution Channel




  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy



By Geography




  • North America (the U.S. and Canada)

  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)

  • Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia- Pacific)

  • Latin America (Brazil, Mexico, Rest of Latin America)

  • The Middle East & Africa (GCC, South Africa, Rest of the Middle East & Africa)



Frequently Asked Questions

The value of the global market was USD 157.33 billion in 2020.

Fortune Business Insights says that the market is projected to reach USD 451.89 billion by 2028.

The value of the market in North America was USD 75.19 billion in 2020.

The market is projected to rise at a CAGR of 14.1% during the forecast period (2021-2028).

The human monoclonal antibody segment is set to lead this market during the forecast period.

Significant investments for the development of novel monoclonal antibody therapeutics and the rising prevalence of chronic diseases are the key factors driving the market.

AbbVie Inc. and F. Hoffmann-La Roche Ltd. are the top players in the market.

North America is expected to hold the highest market share.

Strategic research collaborations are the key trends of the market.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
Monoclonal Antibody Therapy Market Size, Share and Global Industry Trend Forecast till 2026
  • Aug, 2021
  • 2020
  • 2017-2019
  • 135

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X